VRTX – Knox Daily

Analysts Viewpoint

Vertex Pharmaceuticals, Inc [VRTX] Records 50-Day SMA of $467.71

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Vertex Pharmaceuticals,

Insiders Updates

EVP, Chief Scientific Officer ALTSHULER DAVID sold 15 shares of Vertex Pharmaceuticals, Inc [VRTX]

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Analysts Viewpoint

VRTX’s latest rating updates from top analysts.

In a filing, Vertex Pharmaceuticals, Inc revealed its EVP, Chief Scientific Officer ALTSHULER DAVID unloaded Company’s shares for reported $7178.0

Insiders Updates

VRTX (Vertex Pharmaceuticals, Inc) may reap gains as insiders became active recently

Vertex Pharmaceuticals, Inc’s filing revealed that its EVP, Chief Scientific Officer ALTSHULER DAVID unloaded Company’s shares for reported $7178.0 on

Stock Earnings

Selling Buzz: Vertex Pharmaceuticals, Inc [VRTX] EVP, Chief Scientific Officer ALTSHULER DAVID sells 15 shares of the company

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Analysts Viewpoint

Citigroup analysts initates a Buy rating for Vertex Pharmaceuticals, Inc (VRTX)

Vertex Pharmaceuticals, Inc’s recent filing unveils that its EVP, Chief Scientific Officer ALTSHULER DAVID unloaded Company’s shares for reported $7178.0

Analysts Viewpoint

Vertex Pharmaceuticals, Inc [VRTX] Records 50-Day SMA of $473.10

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Stock Earnings

Vertex Pharmaceuticals, Inc (VRTX) Becoming More Attractive for Investors

Vertex Pharmaceuticals, Inc’s recently made public that its EVP, Chief Scientific Officer ALTSHULER DAVID unloaded Company’s shares for reported $7178.0

Insiders Updates

A company insider recently sold 15 shares of Vertex Pharmaceuticals, Inc [VRTX]. Should You Sale?

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or

Analysts Viewpoint

Citigroup analysts initates a Buy rating for Vertex Pharmaceuticals, Inc (VRTX)

In a filing, Vertex Pharmaceuticals, Inc revealed its Officer ALTSHULER DAVID acquired Company’s shares for reported $7178.0 on Nov 15

Tag: VRTX